← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Heparin group
parnaparin
B01AB07
Forms & Strengths
- Injectable solution in pre-filled syringes: 3,250 IU anti-Xa / 0.3 mL
- Injectable solution in pre-filled syringes: 4,000 IU anti-Xa / 0.4 mL
- Injectable solution in pre-filled syringes: 6,400 IU anti-Xa / 0.6 mL
- Injectable solution in pre-filled syringes: 8,000 IU anti-Xa / 0.8 mL
Adult Dosing
- Prophylaxis of deep vein thrombosis in general surgery: 3,250 IU subcutaneously once daily, starting 2 hours before surgery
- Prophylaxis in orthopedic surgery (e.g., hip replacement): 4,000 IU subcutaneously once daily, or weight-adjusted dosing (43 IU/kg)
- Treatment of deep vein thrombosis: 6,400 IU (or 85 IU/kg) subcutaneously every 12 hours for at least 5 days
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established; use is generally not recommended
Indications
- Prophylaxis of venous thromboembolism in general and orthopedic surgery
- Treatment of acute deep vein thrombosis
- Prevention of clotting in the extracorporeal circulation during hemodialysis
Mechanism of Action
- Low molecular weight heparin (LMWH) with a mean molecular weight of 4,000 to 5,000 daltons
- Potentiates the inhibition of coagulation factor Xa by antithrombin III
- Exerts a higher ratio of anti-Xa to anti-IIa (thrombin) activity compared to unfractionated heparin
Contraindications
- Known hypersensitivity to parnaparin, heparin, or pork products
- Active major bleeding conditions or high risk of uncontrolled hemorrhage
- History of immune-mediated heparin-induced thrombocytopenia (HIT)
- Acute bacterial endocarditis
- Severe, uncontrolled hypertension
Adverse Reactions
- Hemorrhage and bleeding complications at various sites
- Injection site hematoma, pain, and bruising
- Heparin-induced thrombocytopenia (HIT) Type I and Type II
- Transient elevations in serum transaminases (AST, ALT)
- Allergic reactions including skin rash and pruritus
Drug Interactions
- Increased risk of bleeding with concomitant antiplatelet agents (e.g., aspirin, clopidogrel, NSAIDs)
- Enhanced hemorrhagic risk when combined with oral anticoagulants (e.g., warfarin, direct oral anticoagulants)
- Additive bleeding effects with systemic glucocorticoids or dextran infusions
Curated Content: Needs Vetting Before Put to Clinical Use